ViroPharma
 |
|
| Public NASDAQ Biotechnology Index | |
| Traded as | NASDAQ: VPHM |
| Industry | Healthcare, Biotechnology, Pharmaceutical company |
| Founded | Exton, Pennsylvania, U.S. (1994) |
| Headquarters | Exton, Pennsylvania, U.S. |
|
Key people
|
Claude H. Nash (founding CEO) Vincent Milano, Chairman and CEO |
| Products | Vancocin |
| Revenue | 132,417,000 USD (2005) |
| 88,145,000 USD (2005) | |
| 113,705,000 USD (2005) | |
|
Number of employees
|
232 |
| Website | www.viropharma.com |
ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.
The company had strategic relationships with GlaxoSmithKline, Schering-Plough, and Sanofi-Aventis. ViroPharma acquired Lev Pharmaceuticals in a merger in 2008.
ViroPharma Incorporated was founded in 1994 by Claude H. Nash (Chief Executive Officer), Mark A. McKinlay (Vice President, Research & Development), Marc S. Collett (Vice President, Discovery Research), Johanna A. Griffin (Vice President, Business Development), and Guy D. Diana (Vice President, Chemistry Research.) None of the founders are still with the company.
In November 2014, Shire plc acquired ViroPharma for$4.2 billion.
Vancocin Pulvules HCl: licensed from Eli Lilly in 2004. Oral Vancocin is an antibiotic for treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis caused by Clostridium difficile.
...
Wikipedia